Structure-Driven Developments of 26S Proteasome Inhibitors

The 26S proteasome is a 2.5-MDa complex, and it operates at the executive end of the ubiquitin-proteasome pathway. It is a proven target for therapeutic agents for the treatment of some cancers and autoimmune diseases, and moreover, it has potential as a target of antibacterial agents. Most inhibito...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annual review of pharmacology and toxicology 2016-01, Vol.56 (1), p.191-209
Hauptverfasser:	led, Pawe, Baumeister, Wolfgang
Format:	Artikel
Sprache:	eng
Schlagworte:	19S regulatory particle AAA ATPase Animals deubiquitylation Drug Discovery - methods Humans Proteasome Endopeptidase Complex - metabolism Proteasome Inhibitors - pharmacology Proteasome Inhibitors - therapeutic use Proteolysis - drug effects structure-based drug design
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!